- RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
This study looks at a new drug called tucatinib for HER2-positive breast cancer that has spread. We want to see if adding tucatinib to standard treatments (trastuzumab and pertuzumab) helps more than a dummy pill (placebo). It also checks for side effects.
For: HER2 Positive Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - RecruitingPHASE2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
This study is for people with HER2-positive breast cancer that has spread. It's testing a new drug called evorpacept alongside standard treatments like trastuzumab and chemotherapy. Researchers want to see if this combination is safe and helps people whose cancer has grown despite previous treatments.
For: Breast Cancer, MetastaticUnited States · Canada · France - RecruitingPHASE3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
This study looks at a new medicine called HLX22, combined with standard treatments, for people newly diagnosed with a certain type of stomach and food pipe cancer. It aims to see how well it works and if it's safe compared to current treatments.
For: Gastroesophageal-junction Cancer · Monoclonal Antibody · Gastric CancerUnited States · Argentina · Australia - RecruitingPHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
This study looks at whether adding a special "targeted" drug after initial treatment for advanced bile duct cancer works better than continuing standard treatment. It customises treatment based on your tumour's unique features.
For: Biliary Tract NeoplasmsBelgium · France · United Kingdom - RecruitingPHASE1, PHASE2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study looks at a new drug, zongertinib, for different HER2+ cancers that have spread. Researchers want to find the best dose, alone and with other treatments, to see if it can shrink tumours.
For: Metastatic Breast Cancer · Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaUnited States · Belgium · China - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - Active not recruitingPHASE1
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
This study is looking at a new medicine called Runimotamab for people with certain advanced HER2-positive cancers. It aims to see if it's safe and how it works, both alone and with other treatments like Trastuzumab.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
This study is looking at a new medicine, RO7771950, for HER2-positive breast cancer that has spread or is hard to remove. It compares RO7771950 with an existing medicine, tucatinib, both given with trastuzumab and capecitabine. The aim is to see if the new medicine works well and is safe.
For: HER2-positive Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This study looks at new drug combinations for stomach or food pipe cancer that has spread. It compares an experimental treatment with standard care, aiming to find better ways to treat patients whose cancer has specific features.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Argentina · Australia - RecruitingPHASE3
The Sagittarius Trial
This study looks at new ways to treat colon cancer after surgery to stop it coming back. It uses advanced tests called 'liquid biopsies' to help doctors choose the best treatment for each person, aiming for better results and fewer side effects.
For: Colon Cancer Stage II · Colon Cancer Stage IIIGermany · Italy · Spain - Active not recruitingPHASE4
Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
This study looks at treating early breast cancer with 6 months of a specific drug (Trastuzumab) after initial treatment, if all cancer cells are gone. It aims to see if a shorter treatment time is still effective, reducing side effects and hospital visits.
For: Breast CancerCanada - Active not recruitingPHASE1
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
This study is testing a new drug, ELVN-002, with existing treatments like trastuzumab and chemotherapy. It's for adults with certain advanced HER2-positive cancers, including breast, stomach, and bowel cancer. The main goal is to find a safe dose and see how well it works.
For: HER2-positive Breast Cancer · HER2-positive Gastric Cancer · HER2 Positive Solid TumorsUnited States · Belgium · France - Active not recruitingPHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
This study looks at new treatments for HER2-positive breast cancer that has spread. It compares an experimental drug, trastuzumab deruxtecan (T-DXd), alone or with another drug, pertuzumab, to standard care, to see if they work better and are safe.
For: Breast Cancer; HER2-positive; MetastaticUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
For: Breast CancerUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
This study looks into a new medicine, patritumab deruxtecan, for HER2-positive breast cancer that has spread and can't be removed by surgery. Researchers want to see if it's safe, how well people tolerate it, and if it can shrink or get rid of the cancer.
For: Breast Neoplasms · Breast CancerUnited States · Canada · Israel - Active not recruitingPHASE1
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
This study looks at a new drug, Inavolisib, for people with solid tumours or breast cancer, focusing on safety and how the body handles it. It's an early-stage study, checking if the drug works alone or with other common cancer treatments.
For: Breast Cancer · Solid TumorUnited States · Canada · France - Active not recruitingPHASE2
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
This study looks at new ways to help patients with stomach or gullet cancer after their regular chemotherapy. It tests if different medicines or close monitoring can keep the cancer under control for longer.
For: Adenocarcinoma of the Oesophagus · Adenocarcinoma of the Gastro-oesophageal Junction · Adenocarcinoma of the StomachUnited Kingdom - RecruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This study is testing if two drugs, trastuzumab and pertuzumab, can treat different types of cancer beyond breast cancer. These drugs work by targeting a specific change in cancer cells called HER2. It's for people aged 12 and over with HER2-positive cancers.
For: Haematological Malignancy · Colorectal Neoplasms · Urinary Bladder NeoplasmUnited Kingdom - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
For: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal AdenocarcinomaArgentina · Australia · Belgium - Active not recruitingPHASE2, PHASE3
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
This study, called ASPEN-06, looked into an experimental drug called Evorpacept for people in the UK with advanced stomach cancer (gastric cancer) that has a specific genetic marker (HER2-positive). It aimed to see if adding Evorpacept to standard treatments improved outcomes. The study has now been stopped due to strategic reasons.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Gastric AdenocarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This study looks at how a drug called tucatinib, combined with trastuzumab, works for various cancers that have a specific change (alteration) in their HER2 gene. It focuses on cancers that have spread or can't be fully removed by surgery.
For: Uterine Neoplasms · Uterine Cervical Neoplasms · Biliary Tract NeoplasmsUnited States · Belgium · Germany - Active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
For: Neoplasm MetastasisUnited States · Australia · Belgium - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
For: HER2-positive Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
This study looks at two drug combinations for HER2-positive breast cancer that has spread. It compares a new drug, zanidatamab, with a standard drug, trastuzumab, both given with chemotherapy, to see which works best and is safest after previous treatments haven't worked.
For: Metastatic HER2-positive Breast CancerUnited States · Australia · Austria